AZ signs agreement for targeted drug delivery research

By Maggie Lynch

- Last updated on GMT

(Image: Getty/Natali_mis)
(Image: Getty/Natali_mis)

Related tags Drug delivery Drug delivery systems Research Astrazeneca Drug delivery technologies Peptide Kidney Technology

AstraZeneca and Aptamer Group will collaborate to leverage Aptamer’s platform for targeted delivery of oligonucelotides to the kidney for therapeutic development.

According to Aptamer, its proprietary technology can be used to determine the feasibility of developing “next generation”​ drug delivery vehicles: Aptamer Drug Conjugates (ApDCs).

Aptamer CEO Arron Tolley told us, “The deal is a significant landmark in the evolution of the company. This deal is a clear demonstration that the technology platform we have developed is being recognized as a superior alternative to current antibody technology.”

The two-year collaboration, Aptamer’s platform technology with AstraZeneca’s experience in cardiovascular, renal and metabolism (CRVM) therapy development, as well as its experience in drug discovery and development. The goal is to use ApDCs to enable targeted delivery to the kidney.

According to AstraZeneca, working with oligonucleotides for targeted drug delivery has posed many challenges previously.

ApDC’s are oligonucleotide or peptide molecules that bind to a target molecule and fold into secondary or tertiary structures. Due to the molecule's mechanism, they have the ability to bind to cell-specific targets and can be attached to therapeutic compounds for target drug delivery. 

Related news

Show more

Related products

show more

Unlock potential in buffer preparation

Unlock potential in buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 18-Sep-2023 | Infographic

Consider how the right partner can help you scale faster, mitigate risks, and optimize resources.

Plan for success with process liquid and buffer preparation

Plan for success with process liquid and buffer preparation

Content provided by Thermo Fisher Scientific - Process Liquid Preparation Services | 14-Aug-2023 | White Paper

Setting the groundwork for successful scale-up is essential for getting a therapeutic to market quickly and efficiently, but navigating the unknowns associated...

Small Molecule development – getting it right

Small Molecule development – getting it right

Content provided by Lonza Small Molecules | 20-Jun-2023 | Insight Guide

Small Molecule drug development is something more and more ambitious emerging pharmaceutical companies are taking on from end to end. But this path can...

Related suppliers

Follow us

Products

View more

Webinars